These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34212184)

  • 1. An adamantamine derivative as a drug candidate for the treatment of visceral leishmaniasis.
    Pomel S; Cojean S; Pons V; Cintrat JC; Nguyen L; Vacus J; Pruvost A; Barbier J; Gillet D; Loiseau PM
    J Antimicrob Chemother; 2021 Sep; 76(10):2640-2650. PubMed ID: 34212184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
    Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
    Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antileishmanial activity and evaluation of the mechanism of action of strychnobiflavone flavonoid isolated from Strychnos pseudoquina against Leishmania infantum.
    Lage PS; Chávez-Fumagalli MA; Mesquita JT; Mata LM; Fernandes SO; Cardoso VN; Soto M; Tavares CA; Leite JP; Tempone AG; Coelho EA
    Parasitol Res; 2015 Dec; 114(12):4625-35. PubMed ID: 26346453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
    de Almeida L; Passalacqua TG; Dutra LA; Fonseca JNVD; Nascimento RFQ; Imamura KB; de Andrade CR; Dos Santos JL; Graminha MAS
    Biomed Pharmacother; 2017 Nov; 95():536-547. PubMed ID: 28866421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
    Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
    Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parasitological and immunological evaluation of a quinoline derivative salt incorporated into a polymeric micelle formulation against Leishmania infantum infection.
    Ribeiro Antinarelli LM; Glanzmann N; Mendonça DVC; Lage DP; Oliveira-da-Silva JA; Tavares GSV; Carvalho AMRS; Freitas CS; Martins VT; Duarte MC; Menezes-Souza D; da Silva AD; Coelho EAF; Soares Coimbra E
    Parasitol Res; 2022 Jul; 121(7):2129-2140. PubMed ID: 35614147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
    Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
    Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo evaluation using phosphatidylserine-liposomes.
    Pinto EG; da Costa-Silva TA; Tempone AG
    Acta Trop; 2014 Sep; 137():206-10. PubMed ID: 24905294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl β-cyclodextrin formulation and pharmacokinetics via intravenous route.
    Balaraman K; Vieira NC; Moussa F; Vacus J; Cojean S; Pomel S; Bories C; Figadère B; Kesavan V; Loiseau PM
    Biomed Pharmacother; 2015 Dec; 76():127-33. PubMed ID: 26653559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileishmanial activity of antiretroviral drugs combined with miltefosine.
    Costa S; Machado M; Cavadas C; do Céu Sousa M
    Parasitol Res; 2016 Oct; 115(10):3881-7. PubMed ID: 27249967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice.
    Cunha-Júnior EF; Andrade-Neto VV; Lima ML; da Costa-Silva TA; Galisteo Junior AJ; Abengózar MA; Barbas C; Rivas L; Almeida-Amaral EE; Tempone AG; Torres-Santos EC
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005281. PubMed ID: 28045892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apigenin is a promising molecule for treatment of visceral leishmaniasis.
    Emiliano YSS; Almeida-Amaral EE
    Front Cell Infect Microbiol; 2023; 13():1066407. PubMed ID: 37091674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antileishmanial activity of terpenylquinones on Leishmania infantum and their effects on Leishmania topoisomerase IB.
    Pérez-Pertejo Y; Escudero-Martínez JM; Reguera RM; Balaña-Fouce R; García PA; Jambrina PG; San Feliciano A; Castro MÁ
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():70-79. PubMed ID: 31678841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functionalized 1,2,3-triazolium salts as potential agents against visceral leishmaniasis.
    das Chagas Almeida A; Meinel RS; Leal YL; Silva TP; Glanzmann N; Mendonça DVC; Perin L; Cunha-Júnior EF; Coelho EAF; Melo RCN; da Silva AD; Coimbra ES
    Parasitol Res; 2022 May; 121(5):1389-1406. PubMed ID: 35169883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo evaluation of anti-Leishmania activity of alkyltriazoles and alkylphosphocholines by oral route.
    Gontijo VS; Colombo FA; Ferreira Espuri P; Freitas PG; Nunes JB; Alves LB; Veloso MP; Alves RB; Freitas RP; Marques MJ
    Exp Parasitol; 2021; 226-227():108123. PubMed ID: 34144040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
    Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
    Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity and Cell-Death Pathway in
    Scariot DB; Volpato H; Fernandes NS; Soares EFP; Ueda-Nakamura T; Dias-Filho BP; Din ZU; Rodrigues-Filho E; Rubira AF; Borges O; Sousa MDC; Nakamura CV
    Front Cell Infect Microbiol; 2019; 9():208. PubMed ID: 31259161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptidomimetic and organometallic derivatives of primaquine active against Leishmania infantum.
    Vale-Costa S; Vale N; Matos J; Tomás A; Moreira R; Gomes P; Gomes MS
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5774-81. PubMed ID: 22926569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.